

# ForPatients

by Roche

Breast Cancer

## A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03558490 ML39208

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a three-month open-label, multicenter, interventional, single arm study located in France, designed to assess feasibility and reliability of the e-Health ZEMY software medical device under investigation for use by participants with breast cancer, who are starting an anti-cancer treatment at any stage of the disease, to manage disease symptoms and anti-cancer treatment-related toxicities while at home.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT03558490 ML39208**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
Female

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---